Covance Is Now Labcorp

We are one global company innovating for millions – together, continuing to bring you more advanced medical breakthroughs.

Study Details

Healthy Non-Smoking Adults, age 18-65 needed

Study Number

8477-257

Group

2

Gender

both

Age

18-65

Location

Madison, Wisconsin

Compensation

$6,933

Study Dates

Dec. 02 - 23, 2021

Additional Information

The investigational drug in this research study is being developed for the treatment of systemic sclerosis and progressive fibrosing interstitial lung disease. Systemic sclerosis (scleroderma) is an autoimmune disorder that affects the skin and internal organs. Progressive fibrosing interstitial lung disease belongs to a group of disorders that make it hard for the lungs to get enough oxygen.

The purpose of Cohort 2 is to evaluate how much of the study drug reaches the blood stream and how long the body takes to get rid of it when taken alone and when taken with nintedanib. Nintedanib is used to treat idiopathic pulmonary fibrosis (scarring of the lungs from an unknown cause).  Information about the safety and tolerability (side effects) of the study drugs will also be collected.

Labcorp Madison, WI is recruiting for:

- Healthy Non-Smoking Adults, age 18-65

- Body Mass Index between 18-32

- Study involves 1 stay of 21 nights and 1 follow-up call

- Compensation up to $6,933 may be provided for time and participation

Details

Call to schedule a screening appointment.

Check-In: Dec 2
Check-out: Dec 23
Follow-up Call: Dec 28

Study Number

8477-257

Group

2

Gender

both

Age

18-65

Location

Madison, Wisconsin

Compensation

$6,933

Study Dates

Dec. 02 - 23, 2021

Additional Information

The investigational drug in this research study is being developed for the treatment of systemic sclerosis and progressive fibrosing interstitial lung disease. Systemic sclerosis (scleroderma) is an autoimmune disorder that affects the skin and internal organs. Progressive fibrosing interstitial lung disease belongs to a group of disorders that make it hard for the lungs to get enough oxygen.

The purpose of Cohort 2 is to evaluate how much of the study drug reaches the blood stream and how long the body takes to get rid of it when taken alone and when taken with nintedanib. Nintedanib is used to treat idiopathic pulmonary fibrosis (scarring of the lungs from an unknown cause).  Information about the safety and tolerability (side effects) of the study drugs will also be collected.

Labcorp Madison, WI is recruiting for:

- Healthy Non-Smoking Adults, age 18-65

- Body Mass Index between 18-32

- Study involves 1 stay of 21 nights and 1 follow-up call

- Compensation up to $6,933 may be provided for time and participation

Details

Call to schedule a screening appointment.

Check-In: Dec 2
Check-out: Dec 23
Follow-up Call: Dec 28

Calculate Your BMI!

Calculate Your BMI!